Bruno Cabrita

Hospital Pedro Hispano

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Ana Luísa Godoy Fernandes

Universidade Federal de São Paulo

Sara Dias

University of Aveiro

Sílvia Correia

Hospital Braga

Gil Gonçalves

University of Coimbra

Jorge Ferreira

Hospital de São Sebastião

António M. Esquinas

Hospital General Universitario Morales Meseguer

Paula Simão

Administração Regional de Saúde de Lisboa e Vale do Tejo

Paula Simão

Hospital Pedro Hispano

Mohamad F. El‐Khatib

American University of Beirut Medical Center

Mohamed E. A. Abdelrahim

Beni-Suef University

Cooperative Institutions

Hospital Pedro Hispano

Centro Hospitalar de Vila Nova de Gaia

Universidade do Porto

Hospital de São João

Administração Regional de Saúde de Lisboa e Vale do Tejo

University of Aveiro

All India Institute of Medical Sciences Raipur

Université Paris Cité

Université de Bourgogne

Hospital General Universitario Morales Meseguer

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Airway stents in malignant central airway obstruction

Pulmonology (2021)

Mariana Serino Cláudia Freitas Sandra Saleiro Bruno Cabrita Miguel Ángel Ruiz Conde

Airway obstruction

10.1016/j.pulmoe.2021.02.003

Cite

Citations (7)

Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study

05.01 - Airway pharmacology and treatment (2021)

Sara Martins Eduarda Tinoco Bruno Cabrita Daniela Machado Inês Franco

Background: Nasal polyposis may impact asthma severity and is a frequent comorbidity in patients with severe eosinophilic asthma. Research has suggested mepolizumab may directly affect upper airway type 2 inflammatory conditions, however there is a lack of clinical studies confirming its effectiveness on nasal symptoms control. Aims: To assess the impact of mepolizumab on nasal symptoms control in patients with severe eosinophilic asthma and nasal polyposis. Methods: A multicenter retrospective study was performed in a cohort of patients with both nasal polyposis and severe refractory asthma treated with mepolizumab. Asthma-related parameters and sino-nasal clinical outcomes were analysed in baseline and 6-12 months after treatment initiation. Results: Twelve patients were included with an average age of 59 years at the start of mepolizumab therapy. The participants were predominantly females (75%) and 58% had history of sinus surgery. After at least 6 months of treatment with mepolizumab, effective control of asthma-related clinical parameters was observed, with a reduction in moderate to severe exacerbations and systemic corticosteroid therapy. In parallel, there was also a statistically significant improvement of sino-nasal symptoms and quality of life, evidenced by a reduction in the average total score on the Sino-Nasal Outcome Test 22, from 70 to 28 points (p= 0.008), and Nasal Congestion scale (range of severe symptoms (3) to mild (1), (p= 0.010)). Conclusions: Mepolizumab demonstrated clinical efficacy in controlling symptoms associated with nasal polyposis in patients with concomitant severe eosinophilic asthma, giving it the advantage of treating both conditions with the same intervention.

Concomitant

Nonallergic rhinitis

Nasal congestion

10.1183/13993003.congress-2021.pa3727

Cite

Citations (6)

Pulmonary Function Tests in Hospitalized Patients/Setting (Specialized Respiratory Care, High Dependency/Intensive Care Unit)

Springer eBooks (2021)

Sara Dias Bruno Cabrita Ana Luísa Godoy Fernandes Márcia Araújo

Acute respiratory failure

Respiratory monitoring

10.1007/978-3-030-76197-4_37

Cite

Citations (1)

The effects of inspiratory muscle training in adults with muscular dystrophy

International Journal of Therapy and Rehabilitation (2022)

Bruno Cabrita Sara Dias Ana Luísa Godoy Fernandes Sílvia Correia Graciete Teixeira

Background/Aims Patients with muscular dystrophy usually have impaired lung function and respiratory muscle strength, leading to pneumonia and respiratory failure, which are significant causes of morbidity and mortality. Inspiratory muscle training might be a safe adjunct treatment to increase the strength and endurance of weakened respiratory muscles. The researchers have developed a new protocol for inspiratory muscle training and evaluated its effect on inspiratory muscle strength and coughing capacity. Methods A total of 12 participants diagnosed with muscle dystrophy and decreased maximal inspiratory pressure (<60 cmH 2 O) participated in this prospective study. Training was individually tailored, starting with low resistance levels and progressing according to tolerance and symptoms. The primary outcome measure was maximal inspiratory pressure. Secondary outcomes were maximal expiratory pressure, peak cough flow and the feasibility of the intervention. Results There were two participants who did not complete the study, and three were lost to follow-up; therefore, only seven patients finished the intervention. In these patients, the authors found a statistically significant improvement in the maximal inspiratory pressure (P=0.018) and peak cough flow (P=0.046) after 3 months of training. There was also an improvement in the maximal expiratory pressure, although this was not statistically significant (P=0.176). Median compliance to training was 99% (94.5–100). Conclusions This intervention led to statistically significant improvements in inspiratory muscles strength and coughing capacity in patients with muscular dystrophy. The results were significantly positive and contribute to the evidence in support of this underused, yet possibly beneficial, treatment, although larger randomised controlled trials are required to verify this.

10.12968/ijtr.2021.0008

Cite

Citations (1)

Functional ability in patients with COPD

09.02 - Physiotherapists (2020)

Ana Machado Sara Souto-Miranda Ana Tavares Ana Oliveira Cristina Jácome

Background: Functional impairment is a critical consequence of COPD. The 1-minute sit-to-stand (1STS) is a valid and reliable test to measure this health domain in patients with COPD, with established reference values. We aimed to quantify the prevalence of functional impairment in patients with COPD and identify the distribution of this impairment across disease stages. Methods: A cross-sectional study with patients with COPD and healthy age-/gender-matched controls was conducted. Spirometry, the modified British Medical Research Council questionnaire (mMRC) and the 1STS were collected. Patients were grouped by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifications. Differences between groups were explored with Kruskal-Wallis and Bonferroni-adjusted pairwise comparisons. Results: 366 patients with COPD (76% male, 67±10y, FEV1 56±21pp) and 345 controls (70% male, 67±9y, FEV₁104±21pp) participated. 50% of the patients presented functional impairment (i.e., performed below 80%predicted). Patients with COPD presented lower functional ability than controls, independently of the GOLD grade/group (Fig. 1). The most symptomatic patients (i.e., GOLD B and D) had the lowest functional levels. Conclusion: Functional ability is reduced in patients with COPD in all GOLD grades/groups, especially in the most symptomatic. Future studies should explore therapeutic interventions to address this problem.

Functional impairment

Obstructive lung disease

Gold standard (test)

Group B

10.1183/13993003.congress-2020.2940

Cite

Citations (1)

Respiratory Physiotherapy and Pulmonary Rehabilitation

Springer eBooks (2021)

Bruno Cabrita Gil Gonçalves André Cabrita Énio Pestana

10.1007/978-3-030-76197-4_22

Cite

Citations (1)

Evaluation of Pressure, Volume, and Flow Waveforms During NIV

Springer eBooks (2021)

Sara Dias António M. Esquinas Bruno Cabrita Ana Luísa Godoy Fernandes

Acute respiratory failure

Respiratory monitoring

10.1007/978-3-030-76197-4_7

Cite

Citations (0)

The Effect of Nutritional Intervention in Nutritional Risk Screening on Hospitalised Lung Cancer Patients

Nutrients (2024)

Raquel Oliveira Bruno Cabrita Ângela Cunha Sónia Silva João Lima

Background: Lung cancer (LC) patients are prone to suffer from malnutrition. Malnutrition negatively affects patients’ response to therapy, increases the incidence of treatment-related side effects, and decreases survival. Early identification of LC patients who are malnourished or at risk of malnutrition can promote recovery and improve prognosis. Objective: This study aimed to assess the risk and nutritional status of lung cancer patients who are hospitalised, as well as to evaluate the impact of nutritional intervention on the risk of malnutrition. Methods: From January 2022 to December 2023, 53 LC patients hospitalised in a pulmonology department had their nutritional risk (initial and final) and nutritional status (initial) assessed. All were selected for nutritional intervention. Nutrition counselling was the first intervention option, along with dietary changes with/without oral nutritional supplements. Results: At the time of hospitalisation, 90.6% of the patients were at nutritional risk, 45.3% were classified as moderately malnourished, and 35.8% were classified as severely underweight. After the hospitalisation, 73.6% were at nutritional risk at the time of discharge, suggesting a statistically significant decrease in the number of patients with nutritional risk. Conclusions: Most LC patients hospitalised presented an altered nutritional status. Our study suggests that a nutritional intervention must be implemented to reduce malnutrition risk, which may impact prognosis. The comprehensive nutritional problems experienced by LC patients require nutritional assessment and improved individually tailored nutritional support.

Underweight

Nutritional Supplementation

Medical nutrition therapy

10.3390/nu17010006

Cite

Citations (0)

Equipment for Pulmonary Function Evaluation: Devices and Technology

Springer eBooks (2021)

Márcia Araújo Sara Dias Bruno Cabrita Bárbara Seabra

Plethysmograph

DLCO

10.1007/978-3-030-76197-4_28

Cite

Citations (1)

Chronic Hypersensitivity Pneumonitis and mortality: impact of comorbidities

Ana Luísa Godoy Fernandes Bruno Cabrita Sara Simões Dias Jorge Ferreira Inês Neves

Introduction: Recently, the inclusion of comorbidities in GAP score has demonstrated a higher discriminative performance in predicting the risk of death comparing to GAP alone in IPF (TORVAN). We performed a mortality analysis in Chronic Hypersensitivity Pneumonitis (cHP) patients, accordingly to ILD-GAP and TORVAN model. Methods: Retrospective analysis of cHP patients, followed in an ILD outpatient department. Results: We included 49 patients, mainly female (32-65.3%) with a median age of 71 years (45-84). The most common comorbidities were systemic hypertension (36-73.5%) and diabetes mellitus (14-28.6%). With ILD-GAP, the patients were divided: 42.9% (n=21) - 0-1 category; 38.8% (n=19)-2-3 category; 16.3% (n=8)-4-5 category and 2.0% (n=1)->5 category Considering TORVAN, the patients (n=46) were divided: 19.6%(n=9) - I category; 19.6%(n=9) - II category; 39.1%(n=18) - III category and 21.7%(n=10) - IV category. Fourteen patients(28.6%) died during follow-up and the median survival time was 29.0 months(5-55). The majority of patients who died were included in stage III and IV(n=13) of TORVAN model. When grouping in binary variables, there was a statistically significant difference between the proportion of deaths in the different categories of TORVAN (stage I-II vs III-IV,p= 0.011) and ILD-GAP (index 1-3 vs >=4,p<0.001). For 1-year mortality, the ILD-GAP and TORVAN score had an AUC of 0.872 (95%CI 0.71-0.99;p=0.015) and 0.726 (95%CI 0.43-0.99;p=0.139), respectively. Conclusion: In our sample of cHP, the ILD-GAP and the TORVAN were associated with mortality, however, ILD-GAP seems to have a better predictive value than TORVAN. Larger studies are needed to evaluate the impact of these scores.

Hypersensitivity pneumonitis

10.1183/13993003.congress-2020.3001

Cite

Citations (0)